Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338591 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| Ammonia Solution, Strong SCHEMBL7207615 | 0.98 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL422229 | 0.90 | CYP2C9 (0.70) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL23596366 | 0.89 | CHRNB2 (0.60) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL20730105 | 0.89 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL19055583 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9367178 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL4888697 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL30542607 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL3229561 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452681-A | Quantum dot solution and preparation method thereof | TCL CORP | 2019-11-15 | — | — | CN | claimed |
| CN-101687815-A | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI AVENTIS | 2010-03-31 | — | — | CN | claimed |
| CN-101687865-A | A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI AVENTIS | 2010-03-31 | — | — | CN | claimed |
| EP-4318630-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-14 | — | — | US | disclosed |
| EP-4415105-A2 | NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE | Asahi Kasei Kabushiki Kaisha (JP) | 2024-08-14 | — | — | EP | disclosed |
| US-20240178452-A1 | Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| EP-4318630-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117223143-A | Nonaqueous electrolyte and nonaqueous secondary battery | 旭化成株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-1434810-A | Piperidyloxy and pyrrolidinophenyl oxazolidinones as antibacterial agents | ORTHO MCNEIL PHARM INC (US) | 2003-08-06 | — | — | CN | disclosed |
| CN-1395562-A | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2003-02-05 | — | — | CN | disclosed |
| CN-1336930-A | Bridged heterocyclic derivatives | GPINIL HOLDING CORP (US) | 2002-02-20 | — | — | CN | disclosed |
| CN-1296478-A | Histamine H3 receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-05-23 | — | — | CN | disclosed |
| CN-1271354-A | Compounds possessing neuronal activity | VERTEX PHARMA (US) | 2000-10-25 | — | — | CN | disclosed |
| CN-1045962-C | Pyridopyridazinone or pyridinopyridazinethione compounds, intermediates for their preparation, pharmaceutical compositions containing them and their use | SYNTEX INC (US) | 1999-10-27 | — | — | CN | disclosed |
| CN-1211244-A | Radicicol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1999-03-17 | — | — | CN | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| CN-1088927-A | Benzo and pyrido pyridazinone and pyridazinthione compounds | SYNTEX A INC (US) | 1994-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | CHRNB2 117/4885CHRNA4 214/4885CYP3A4 850/4885 |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | CLK2, TYK2, CLK3 | CHRNB2 748/4885CHRNA4 1620/4885CYP3A4 3798/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | CHRNB2 117/4885CHRNA4 214/4885CYP3A4 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.